Elad Sharon, Clinical and Translational Director, Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Co-Chair, Alliance Immuno-Oncology Committee at Alliance for Clinical Trials in Oncology, shared a post on X:
“Wonderful news from Norman Sharpless today regarding NIH appropriations. For the time being, we can breathe a sigh of relief on NIH and NCI funding and focus on improving our science and treating patients!”
Quoting Norman Sharpless’, Managing Director at Jupiter Bioventures and Professor of Cancer Policy and Innovation at UNC School of Medicine, LinkedIn post:
“Good news on the NIH Appropriations front for FY26. The joint House-Senate package increases NIH funding by $415M (including $128M for NCI). Congress blocks cuts to indirects, prohibits a Draconian increase in multi-year funding, and we still will have 28 institutes and centers. While the full Congress has to pass this and the POTUS has to sign it, it appears that the reports of the demise of American biomedical research have been exaggerated.”
More posts featuring Elad Sharon.